Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | TACR3 | P29371 | 10/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | CCL5 | P13501 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366381 | 0.88 | CYP2C9 (0.45) | CYP2C9TACR3PPARGWDR5 | |
| SCHEMBL7916360 | 0.88 | CYP2C9 (0.44) | CYP2C9TACR3PPARGWDR5 | |
| SCHEMBL12149114 | 0.88 | CYP2C9 (0.44) | CYP2C9TACR3PPARGWDR5 | |
| SCHEMBL1364253 | 0.87 | CYP2C9 (0.45) | CYP2C9TACR3PPARGPDE2A | |
| SCHEMBL1364148 | 0.87 | CYP2C9 (0.43) | CYP2C9TACR3CNR1CNR2PPARG | |
| SCHEMBL12149149 | 0.87 | CYP2C9 (0.45) | CYP2C9TACR3MAPK1PPARG | |
| SCHEMBL1364576 | 0.85 | CYP2C9 (0.45) | CYP2C9TACR3PDE2A | |
| SCHEMBL1365439 | 0.85 | CYP2C9 (0.43) | CYP2C9TACR3CNR1CNR2PPARG | |
| SCHEMBL7913126 | 0.85 | CYP2C9 (0.43) | CYP2C9TACR3CNR1CNR2WDR5 | |
| SCHEMBL11917814 | 0.85 | CYP2C9 (0.47) | CYP2C9TACR3MAPK1PPARGPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-11-24 | — | — | US | disclosed |
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNK3, KCNQ3, KCNN3 | CYP2C9 2420/4885TACR3 36/4885CNR1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.